DOCSLIB.ORG

Ministry of Health Essential Medicines List for Uganda EMLU 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ministry of Health Essential Medicines List for Uganda EMLU 2007 Ministry of Health Essential Medicines List for Uganda EMLU 2007 Essential Medicines List for Uganda 2007 © 2007 Ministry of Health All parts of this publication may be reproduced in any form, provided due acknowledgement is given Copies may be obtained from: The Principal Pharmacist Ministry of Health PO Box 7272, Kampala Uganda Ministry of Health Building Room C 105 Plot 6 Lourdel Road Wandegeya, Kampala Tel: 077-2512975 Email: [email protected] or [email protected] Printed and Bound by: Table of Contents Foreword............................................................................viii Preface................................................................................ xi Acknowledgements ............................................................xiii Essential Medicines Review committee ............................ xiv Contributing Clinical Specialists ......................................... xv Presentation of Information............................................... xvi Abbreviations and Units ...................................................xviii Summary of Main Changes in EDLU 2007 ..........................1 1. ANAESTHETICS .............................................................4 1.1 General anaesthetics and oxygen....................4 1.2 Local anaesthetics ...........................................4 1.3 Preoperative and peri-operative medication.....5 2. ANALGESICS, ANTIPYRETICS......................................5 2.1 Non-opioids......................................................5 2.2 Medicines used for gout...................................5 2.3 Opioid analgesics.............................................5 3. ANTI-ALLERGICS & MEDICINES USED IN ANAPHYLAXIS ...........................................................6 4. ANTIDOTES ....................................................................6 4.1 General ............................................................6 4.2 Specific ............................................................6 5. ANTIEPILEPTICS AND ANTICONVULSANTS................7 6. ANTI-INFECTIVE MEDICINES........................................7 6.1 Anthelmintics....................................................7 6.1.1 Intestinal anthelminthics................................7 6.1.2 Antifilarials.....................................................7 6.1.3 Antischistosomals .........................................8 6.2 Antibacterials ...................................................8 6.2.1 Beta Lactam Medicines.................................8 6.2.2 Other antibacterial medicines........................8 EMLU 2007 iii 6.2.3 Antileprosy medicines ...................................9 6.2.4 Antituberculosis medicines............................9 6.3 Antifungal medicines........................................9 6.4 Antiprotozoal medicines.................................10 6.4.1 Antiamoebic medicines ...............................10 6.4.2 Antileishmaniasis medicines .......................10 6.4.3 Antimalarial medicines ................................10 6.4.4 Antitrypanosomal medicines (African trypanosomiasis).......................................10 6.4.5 Antitrichomoniasis medicines......................10 6.4.6 Medicines used in toxoplasmosis................10 6.5 Antiviral medicines .........................................11 7. ANTIMIGRAINE MEDICINES ........................................11 7.1 Treatment of Acute Attacks............................11 7.2 Prophylaxis ....................................................11 8. ANTINEOPLASTIC & IMMUNOSUPPRESSIVE MEDICINES ..............................................................11 8.1 Immunosuppressive medicines......................11 8.2 Cytotoxic medicines .......................................11 8.3 Hormones and antihormones.........................12 9. ANTI-PARKINSONISM MEDICINES .............................12 10. MEDICINES AFFECTING THE BLOOD ......................12 10.1 Antianaemia medicines ................................12 10.2 Anticoagulants and antagonists ...................12 10.3 Fibrinolytic Medicines...................................13 11. BLOOD PRODUCTS & PLASMA SUBSTITUTES.......13 11.1 Plasma expanders .......................................13 11.2 Plasma extracts ...........................................13 12. CARDIOVASCULAR MEDICINES...............................13 12.1 Antianginal medicines ..................................13 12.2 Antidysrhythmic medicines...........................13 12.3 Antihypertensive medicines .........................13 iv EMLU 2007 12.4 Medicines used in heart failure ....................14 12.4.1 Cardiac glycosides ....................................14 12.4.2 Medicines used in vascular shock.............14 13. DERMATOLOGICAL MEDICINES...............................14 13.1 Topical antifungals .......................................14 13.2 Topical antiinfectives....................................14 13.3 Topical antiinflammatories and antipruritics .15 13.4 Keratoplastics and keratolytics.....................15 13.5 Scabicide .....................................................15 13.6 Pediculicide..................................................15 13.7 Other topical preparations............................15 14. DIAGNOSTIC MEDICINES..........................................15 14.1 Ophthalmic diagnostic medicines1 ...............15 14.2 Radiocontrast media ....................................16 15. DISINFECTANTS and ANTISEPTICS .........................16 15.1 Antiseptics....................................................16 15.2 Disinfectants ................................................16 16. DIURETICS..................................................................16 17. GASTROINTESTINAL MEDICINES ............................17 17.1 Antacids and other antiulcer medicines........17 17.2 Antiemetics ..................................................17 17.3 Antihaemorrhoidals ......................................17 17.4 Antispasmodics............................................17 17.5 Laxatives......................................................17 17.6 Medicines used in diarrhoea ........................17 17.6.1 For oral rehydration...................................17 17.6.2 Antidiarrhoeals1.........................................18 18. HORMONES, OTHER ENDOCRINE MEDICINES & CONTRACEPTIVES .................................................18 18.1 Adrenal hormones & synthetic substitutes ...18 18.2 Androgens....................................................18 18.3 Hormonal contraceptives .............................18 v EMLU 2007 18.4 Oestrogens ..................................................19 18.5 Insulins and other antidiabetic medicines.....19 18.6 Ovulation inducers .......................................19 18.7 Progestogens...............................................19 18.8 Thyroid hormones and antithyroid medicines19 19. IMMUNOLOGICALS2...................................................19 19.1 Immunological diagnostic medicines............19 19.2 Sera and immunoglobulins...........................19 19.3 Vaccines ......................................................20 19.3.1 Vaccines for routine immunisation ............20 19.3.2 Vaccines for specific groups of individuals 20 20. MUSCLE RELAXANTS & CHOLINESTERASE INHIBITORS .............................................................20 21. OPHTHALMOLOGICAL PREPARATIONS..................21 21.1 Antiinfective medicines.................................21 21.1.1 Antiinfective + antiinflammatory Medicines1 .................................................................21 21.2 Antiinflammatory medicines1 ........................21 21.3 Local anaesthetics1 ......................................22 21.4 Miotics and antiglaucoma medicines1 ..........22 21.5 Mydriatics.....................................................22 21.6 Astringents1..................................................22 22. OXYTOCICS & ANTI-OXYTOCICS .............................22 22.1 Oxytocics .....................................................22 22.2 Antioxytocics ................................................22 23. PERITONEAL & HAEMODIALYSIS SOLUTIONS .......22 24. PSYCHOTHERAPEUTIC MEDICINES........................23 25. MEDICINES ACTING ON THE RESPIRATORY TRACT ..................................................................................23 25.1 Antiasthmatic medicines ..............................23 25.2 Antitussive Medicines...................................24 25.3 Cough soothing preparation.........................24 vi EMLU 2007 26. SOLUTIONS CORRECTING WATER, ELECTROLYTE, & ACID-BASE DISTURBANCES ..............................24 26.1 For oral rehydration......................................24 26.2 Parenterals...................................................24 26.3 Miscellaneous ..............................................24 27. VITAMINS & MINERALS .............................................24 28. EAR, NOSE & OROPHARYNGEAL PREPARATIONS25 28.1 Ear preparations ..........................................25 28.2 Nasal preparations.......................................25 28.3 Oropharygeal preparations ..........................25 29. MEDICINES FOR NEUROSURGICAL USE ................26 29.1 For cerebral metabolism/perfusion...............26 30 ANTIRETROVIRAL MEDICINES ..............................26 30.1 Nucleoside reverse transcriptase inhibitors (NRTI) ..26 30.2 Protease Inhibitors (PI) ............................................26 30.3 Non – Nucleoside Reverse Transcriptase
Load more

Recommended publications
  • Characterization of the Soil Nematode Fauna of Makerere Hill, Kampala, Uganda
    Vol. 11(6), pp. 70-84, Oct-Dec 2019 DOI: 10.5897/JEN2019.0239 Article Number: F82FA2462098 ISSN 2006-9855 Copyright ©2019 Author(s) retain the copyright of this article Journal of Entomology and Nematology http://www.academicjournals.org/JEN Full Length Research Paper Characterization of the Soil Nematode Fauna of Makerere Hill, Kampala, Uganda Nzeako S. O.1*, Talwana H.2, Teye E.3, Sekanjako I.2, Nabweteme J.2 and Businge M. A.3 1Department of Animal and Environmental Biology, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria. 2Department of Agriculture Engineering, University of Cape Coast, College of Agriculture and Natural Science, School Agriculture, Cape Coast, Ghana. 3School of Agricultural Sciences, College of Agricultural and Environmental Sciences, Makerere University, Makerere, Kampala, Uganda. Received 17 June, 2019; Accepted 13 August, 2019 Soil nematode faunal analysis is necessary to ascertain the health status of the soil ecosystem. Composite soil samples were taken at designated sites; A, B, C and D from the Makerere Hill area, Kampala and analyzed to characterize the nematode fauna status. Soil samples were collected vertically at 0-5 cm, 5-10 cm and 10-15 cm core depths with a 5 cm wide soil auger. A total of 7,900 nematodes were collected from the study out of which 1,720 (21.8%) nematodes came from 0-5 cm core depth, 5,270 (66.7) from 5-10 cm core depth and 910 (11.52) from the 10-15 cm core depth. Species diversity showed nine orders of nematodes comprising twenty four families and forty nine species.
    [Show full text]
  • Chapter 5 Traffic Survey and Traffic Demand Forecast
    Final Report – Executive Summary The Study on Greater Kampala Road Network and Transport Improvement in the Republic of Uganda November 2010 CHAPTER 5 TRAFFIC SURVEY AND TRAFFIC DEMAND FORECAST 5.1 TRAFFIC SURVEY The Study Team conducted a traffic survey in January 2010 to identify the current traffic condition and to forecast the future traffic demand. A supplemental traffic survey was also conducted on major junctions in June 2010 to study the current intersection condition and problems. The objective, method and coverage of six types of traffic survey are summarized as below: Table 5.1.1 Outline of Traffic Survey Survey Objectives Method Coverage To obtain traffic volumes on 12 locations (12hr) Traffic Count Survey Vehicular Traffic Count major roads 2 locations (24hr) Origin-Destination (O-D) To capture trip information of Interview with drivers at 9 locations Survey vehicles roadsides To obtain traffic volumes and Intersection Traffic Count movement at major Vehicular Traffic Count 2 locations Survey intersections To collect information about Taxi (Minibus) Passenger and Interview with taxi public transport driver and 5 major taxi parks Driver Interview Survey drivers and users users, and their opinions Boda-Boda (Bike Taxi) To collect information about Interview with boda-boda 6 areas on major Passenger and Driver boda-boda drivers and users, drivers and users roads Interview Survey and their opinions To collect information on Actual driving survey by Travel Speed Survey present traffic situation on passenger car major roads Source: JICA Study Team Actual traffic survey was conducted from January to February 2010. Each type of survey schedule is shown in below figure: 2009 2010 Survey Dec.
    [Show full text]
  • Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated Falciparum Malaria (Review)
    Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Omari AAA, Gamble CL, Garner P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 9 AUTHORS’CONCLUSIONS . 9 ACKNOWLEDGEMENTS . 10 REFERENCES ..................................... 10 CHARACTERISTICSOFSTUDIES . 13 DATAANDANALYSES. 20 Analysis 1.1. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 1 Total failure by day 28. 22 Analysis 1.2. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 2 Total failure by day 14. 23 Analysis 1.3. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 3 Gametocyte carriage on day 14. 23 Analysis 2.1. Comparison 2 Artemether-lumefantrine vs chloroquine plus sulfadoxine-pyrimethamine, Outcome 1 Total failurebyday28. ................................ 24 Analysis 2.2. Comparison 2 Artemether-lumefantrine
    [Show full text]
  • Money Remitters As at March 10, 2020 No
    LICENCED MONEY REMITTERS AS AT MARCH 10, 2020 NO. NAME ADDRESS TELEPHONE EMAIL ADDRESS 1 ACCESS P.O.Box 27632 Kampala, Shop No.12 Krish Mall, Old Portbell Road, Bugolobi, Kampala. 0414-223508 [email protected] 2 AMAL P.O.Box 10363 Kampala, Plot No.1 Central Lane, Arua 0753-819042 [email protected] 3 ASHANTI P.O. Box 31364, Plot 5B Wilson Road, Shop No. F-2, Arua Park Mall, Kampala. 0772-246065 [email protected] 4 ASIAN OVERSEAS EXCHANGE P.O. Box 7669, Kampala, Plot No. 4A Kampala Road, Crown House, Shop No. 1, Ground Floor. 0754-885881 [email protected] 5 BAKAAL P.O.Box 10161 Kampala, Plot 82 Ben Kiwanuka Street, Tropical Complex, Kampala. 0772-097027 [email protected] 6 BEST P.O. Box 22701 Kampala , Plot No. 25A&B William Street, Trade Link Building, Level 2, Kampala 0712-729729 [email protected] 7 BEST RATES P.O.Box 31448, Kampala , Capital Shoppers Shopping Centre, Shop 1 Ntinda Road, Kampala. 0705-734431 [email protected] 8 BICCO P.O. Box 3307, Kampala,Plot 13, Buganda Road, Mukwano Courts, Shop No. G-02, Kampala. 0414-252428 [email protected] 9 BRAVE P.O. Box 75666, Kampala, Plot 505 Bombo Road, Block 38 Kagugube, Wandegeya. 0772-333370 [email protected] 10 BT PAYMENTS P.O. Box 2455, KampalaGuardian Building, Plot No. 67A, Spring Road, Bugolobi [email protected] 11 BUDDU P.O.Box 23442 Kampalak, Plot No. 22A, Shop No.L3-662/3, Gaza land Plaza, William Street, Kampala 0414-340397 [email protected] 12 CAPITAL P.O.
    [Show full text]
  • Approved Bodaboda Stages
    Approved Bodaboda Stages SN Division Parish Stage ID X-Coordinate Y-Coordinate 1 CENTRAL DIVISION BUKESA 1001 32.563999 0.317146 2 CENTRAL DIVISION BUKESA 1002 32.564999 0.317240 3 CENTRAL DIVISION BUKESA 1003 32.566799 0.319574 4 CENTRAL DIVISION BUKESA 1004 32.563301 0.320431 5 CENTRAL DIVISION BUKESA 1005 32.562698 0.321824 6 CENTRAL DIVISION BUKESA 1006 32.561100 0.324322 7 CENTRAL DIVISION INDUSTRIAL AREA 1007 32.610802 0.312010 8 CENTRAL DIVISION INDUSTRIAL AREA 1008 32.599201 0.314553 9 CENTRAL DIVISION KAGUGUBE 1009 32.565701 0.325353 10 CENTRAL DIVISION KAGUGUBE 1010 32.569099 0.325794 11 CENTRAL DIVISION KAGUGUBE 1011 32.567001 0.327003 12 CENTRAL DIVISION KAGUGUBE 1012 32.571301 0.327249 13 CENTRAL DIVISION KAMWOKYA II 1013 32.583698 0.342530 14 CENTRAL DIVISION KOLOLO I 1014 32.605900 0.326255 15 CENTRAL DIVISION KOLOLO I 1015 32.605400 0.326868 16 CENTRAL DIVISION MENGO 1016 32.567101 0.305112 17 CENTRAL DIVISION MENGO 1017 32.563702 0.306650 18 CENTRAL DIVISION MENGO 1018 32.565899 0.307312 19 CENTRAL DIVISION MENGO 1019 32.567501 0.307867 20 CENTRAL DIVISION MENGO 1020 32.567600 0.307938 21 CENTRAL DIVISION MENGO 1021 32.569500 0.308241 22 CENTRAL DIVISION MENGO 1022 32.569199 0.309950 23 CENTRAL DIVISION MENGO 1023 32.564800 0.310082 24 CENTRAL DIVISION MENGO 1024 32.567600 0.311253 25 CENTRAL DIVISION MENGO 1025 32.566002 0.311941 26 CENTRAL DIVISION OLD KAMPALA 1026 32.567501 0.314132 27 CENTRAL DIVISION OLD KAMPALA 1027 32.565701 0.314559 28 CENTRAL DIVISION OLD KAMPALA 1028 32.566002 0.314855 29 CENTRAL DIVISION OLD
    [Show full text]
  • Local Pharmaceutical Production Challenges (1)-1.Pdf
    PROMOTING LOCAL PHARMACEUTICAL PRODUCTION IN UGANDA Challenges facing local pharmaceutical firms Report of A Survey conducted June 2013 social justice in health CEHURD Center for Health, Human Rights and Development The Center for Health, Human Rights and Development (CEHURD) research and advocacy organization is an indigenous, non-profit, which is pioneering the justiciability of the right to health in the East African Region. Started in 2007 and formally registered in 2009, CEHURD was founded to contribute towards ensuring that public health laws are used as principle tools for the promotion and protection of public health of the vulnerable populations in Uganda and in the East African region. Our mission is to work towards cantered health system and ensure an effective, equitable, people- the full realization of the right to health and promote respect for human rights. For more information: CEHURD: Center for Health, Human Rights and Development Plot 614 Tufnell Drive, Kamwokya P.O Box 16617 Wandegeya, Kampala, Uganda Telephone: +256 414 532283 Email: [email protected] www.cehurd.org CEHURD: Social Justice in Health TABLE OF CONTENts ACRONYMS ................................................................................................................. II EXECUTIVE SUMMARY ......................................................................................... III ACKNOWLEDGEMENTS ........................................................................................ IV INTRODUCTION ......................................................................................................
    [Show full text]
  • Approved Branches Kampala Metropolitan and Upcountry2017
    Approved Branches Kampala Inspection and Metropolitan and Compliance Department Upcountry2017 Table of Contents Fundamental/core requirements/conditions (must meet) ..................................................................................................................................................................... 3 Non fundamental requirements/conditions (correctable) ..................................................................................................................................................................... 4 KAMPALA METROPOLITAN AREA .............................................................................................................................................................................................. 5 Casino Inspection Details ............................................................................................................................................................................................................. 5 Betting Premises Inspection Details ............................................................................................................................................................................................ 6 Eldorado Company Limited T/A Premier Bet ..................................................................................................................................................................... 6 Top Bet Sports Betting Limited T/A Top Bet.......................................................................................................................................................................
    [Show full text]
  • Information for the User Riamet® 20 Mg/120 Mg Tablets Artemether And
    Package leaflet: Information for the user Riamet® 20 mg/120 mg tablets artemether and lumefantrine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. (See section 4). What is in this leaflet 1. What Riamet is and what it is used for 2. What you need to know before you take Riamet 3. How to take Riamet 4. Possible side effects 5. How to store Riamet 6. Contents of the pack and other information 1. What Riamet is and what it is used for Riamet contains two substances called artemether and lumefantrine. They belong to a group of medicines called anti-malarials. Riamet is only used for the treatment of acute uncomplicated malaria infections caused by a parasite called “Plasmodium falciparum”. This parasite is a tiny organism made up of one cell that is found inside red blood cells. Riamet is used to treat adults, children and infants of 5 kg body weight and above. Riamet is not used to prevent malaria or to treat severe malaria (where it has affected the brain, lungs or kidneys).
    [Show full text]
  • Behavioural Influences on Attitudes Towards Petty Corruption a Study of Social Norms and Mental Models in Uganda
    Behavioural influences on attitudes towards petty corruption A Study of Social Norms and Mental Models in Uganda Claudia Baez-Camargo, Paul Bukuluki, Robert Lugolobi, Cosimo Stahl, Saba Kassa December 2017 Basel Institute on Governance Steinenring 60 | 4051 Basel, Switzerland | +41 61 205 55 11 [email protected] | www.baselgovernance.org BASEL INSTITUTE ON GOVERNANCE This document is an output from a project funded by the UK Department for International Development (DFID) through the Research for Evidence Division (RED) for the benefit of developing countries. However, the views expressed and information contained in it are not necessarily those of or endorsed by DFID, which can accept no responsibility for such views or information or for any reliance placed on them. Dr Claudia Baez-Camargo, University of Basel, Basel Institute on Governance, Steinenring 60, 4051 Basel, Switzerland, [email protected] Assoc Prof Paul Bukuluki, Makerere University, Makerere Hill Road - Wandegeya, Kampala, Uganda, [email protected] Mr Robert Lugolobi, Independent consultant Kampala, [email protected] Mr Cosimo Stahl, Basel Institute on Governance, Steinenring 60, 4051 Basel, Switzerland, [email protected] Dr Saba Kassa, Basel Institute on Governance, Steinenring 60, 4051 Basel, Switzerland, [email protected] BASEL INSTITUTE ON GOVERNANCE Table of contents Acronyms 1 1 Introduction 3 2 Research Design 5 2.1 Rationale and conceptual approach 5 2.2 Research design and methods 6 3 Uganda: Background
    [Show full text]
  • The Republic of Uganda Ministry of Health Press
    THE REPUBLIC OF UGANDA MINISTRY OF HEALTH PRESS STATEMENT UPDATE ON COVID-19 RESPONSE IN UGANDA 22 December 2020 Dr. Joyce Moriku Kaducu Minister of State for Health in charge of Primary Health Care 22nd December 2020 - The Ministry of Health would like to update the general public on the status of the COVID-19Pandemic in Uganda. OVERVIEW OF COVID-19 - THE NEW VARIANT STRAIN The Ministry of Health is closely followingthe global trends of a new variant strain (501. V2) of SARSCoV-2that has been reported in the United Kingdom, other parts of Europe and now South Africa and Nigeria. It has been shown to spread much faster but so far no evidence of high severity than the first strain. So far, we know that the new variant strain is spreading faster than what we experienced in the 1st wave. It is important to note that this new variant strain has NOT been reported in Uganda. The Ministry of Health working with regional partners, Africa CDC through Uganda Virus Research Institute (UVRI)will start genome surveillance for the new strain to determine its prevalence in the country. However, we know that the transmission of the virusxand the control measures remain the same as the virus in the 1st wave. i.e. Consistent mask use, social distancing and good hand hygiene. COVID-19 IN UGANDA As you are all aware, Uganda is in phase 4 of the pandemic. This means that there is intense and widespread community transmission of COVID-19in nearly all districts and with occasional and emerging hotspots.
    [Show full text]
  • Acknowledgement: the Authors Are Grateful for Financial Support from the Netherlands Ministry of Agriculture, Nature and Food Qu
    PARTNERSHIPS FOR HEALTHY DIETS AND NUTRITION IN URBAN AFRICAN FOOD SYSTEMS – EVIDENCE AND STRATEGIES “THE KANYANYA FOOD CHALLENGE – FOOD SYSTEMS MAPPING” PROGRESS REPORT DELIVERABLE WP1: NOURICITY - KAMPALA Vincent Linderhof, Youri Dijkxhoorn (both Wageningen Economic Research), Joel Onyango (BoP innovation centre), Andrea Fongar (Bioversity International), and Martha Nalweyiso Date of the report 31-12-2019 Acknowledgement: The authors are grateful for financial support from the Netherlands Ministry of Agriculture, Nature and Food Quality (grant number BO-43-003.02-009 as part of LEAP-Agri program), and the flagship program Food Systems for Healthier Diets of the CGIAR program Agriculture for Nutrition and Health (A4NH). 1 | The Kanyanya food challenge Contents Glossary ............................................................................................................................ 3 List of figures ..................................................................................................................... 5 List of tables ...................................................................................................................... 6 1 Introduction ................................................................................................................. 7 2 Desk study ................................................................................................................... 8 1.1 2.1 Description of Kampala .................................................................................... 8
    [Show full text]
  • The Republic of Uganda in the Court of Appeal of Uganda at Kampala Civil Appeal No. 20 of 2009 Cise Dispensers (U) Ltd
    THE REPUBLIC OF UGANDA IN THE COURT OF APPEAL OF UGANDA AT KAMPALA 5 CIVIL APPEAL NO. 20 OF 2009 CISE DISPENSERS (U) LTD :::::::::::::::::::::::::::::::::::::::::: APPELLANT VERSUS EXECUTIVE SECRETARY, 10 NATIONAL DRUG AUTHORITY::::::::::::::::::::::::::::::::: RESPONDENT CORAM: HON JUSTICE A.E.N MPAGI-BAHIGEINE, JA HON JUSTICE C.K BYAMUGISHA, JA HON JUSTICE S.B.K. KAVUMA, JA 15 (Appeal from the decision of High Court of Kampala (Justice Elizabeth Musoke) dated the 22nd December 2008 in Misc. Application No. 355/2008) JUDGEMENT OF A.E.N MPAGI-BAHIGEINE, JA 20 This is a first appeal, arising out of the judgement of the High Court, dated 22nd December 2008, dismissing Miscellaneous Application No. 0355/08, vide which the appellant was seeking orders of certiorari, mandamus, a permanent injunction and a number of declarations against the respondent. 25 The background. The appellant operated an Allied Professional Health Unit in Rubaga Division, Kampala District. On 25-07-08, officials from the respondent accompanied by some police officers entered the appellant’s premises which they inspected, searched and 30 impounded some drugs found thereon. They listed them as appears in Annexture ‘B’ to the appellant’s affidavit. The respondent claimed that the premises were not licensed. The impounded drugs were taken to the CID Headquarters at Kibuli. The Manager of the appellant was 1 arrested and taken to Wandegeya Police Station. The appellant has, since the inspection, stopped its operation of the Health Unit. Mr. Kituuma-Magala appeared for the Appellant while Ms. Ruth Sebatindira was for 5 the Respondent. The appeal consists of three grounds: 1.
    [Show full text]